(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) issued a clinical data update for the phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma patients. The preliminary interim data includes: 100% disease control rate; ad 31% overall response rate. The company said these data provide clinical proof-of-concept for the combination treatment.
IDEAYA noted that it had cash, cash equivalents and marketable securities of approximately $386 million as of September 30, 2021, which it believes will fund its planned operations into 2025.
Shares of IDEAYA Biosciences were up 2% in pre-market trade on Tuesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
